We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.27%
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $219.44 · 29 analysts
Stored first · Google News · Yahoo Finance (English)
Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector? - simplywall.st
Is Biogen (BIIB) Fairly Valued On FDA Approval Of Its New Leqembi Autoinjector? simplywall.st
First-At-Home Alzheimer's Treatment: US FDA Approves Eisai-Biogen's Weekly Self-Injection - NDTV Profit
First-At-Home Alzheimer's Treatment: US FDA Approves Eisai-Biogen's Weekly Self-Injection NDTV Profit
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - The Economic Times
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug The Economic Times
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug | Business Information & News | FE - Westlaw Today
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug | Business Information & News | FE Westlaw Today
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Tr - GuruFocus
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Tr GuruFocus
FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug - PharmaLive
FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug PharmaLive
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $1.94 | — | — | $2.42B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.64 | — | — | $2.43B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $9.35 | — | — | $7.22B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $6.7 | — | — | $4.76B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 27. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 15. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 02. | Citigroup | — | Maintain | Neutral → Neutral | — | Citigroup: Neutral |
| 2026. 05. 01. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 05. 01. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 01. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
As of FY2023Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,813,192 | $495.09M | 0.81% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 809,617 | $148.43M | 0.27% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 251,763 | $44.31M | 0.07% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 9,444 | $1.73M | 0.00% | — | New position |